Skip to main content
Fig. 4 | BMC Medicine

Fig. 4

From: Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint

Fig. 4

Predicted age-specific time-varying efficacy against both prototype strains and the Delta variant across three clinical endpoints. A SARS-CoV-2 infection, B symptomatic COVID-19, and C severe COVID-19. The number on the top of the bar represents the predicted efficacy, and the vertical line represents the 95% confidence interval

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us